OncoCube Therapeutics develops innovative cancer therapies targeting Transforming acidic coiled-coil 3 (TACC3) in a broad range of cancers.
OncoCube Therapeutics was founded by three dedicated scientists who have expertise in medicinal chemistry, cancer biology, and drug discovery. OncoCube aims to treat patients with genetically defined aggressive cancers, thereby providing great benefits to cancer patients without serious side effects.